Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sunshine Biopharma (SBFMW) Tax Provisions (2022 - 2025)

Historic Tax Provisions for Sunshine Biopharma (SBFMW) over the last 4 years, with Q3 2025 value amounting to -$137438.0.

  • Sunshine Biopharma's Tax Provisions fell 16386.02% to -$137438.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$515502.0, marking a year-over-year decrease of 55161.64%. This contributed to the annual value of -$234858.0 for FY2024, which is 15943.27% down from last year.
  • Per Sunshine Biopharma's latest filing, its Tax Provisions stood at -$137438.0 for Q3 2025, which was down 16386.02% from -$209166.0 recorded in Q2 2025.
  • Sunshine Biopharma's Tax Provisions' 5-year high stood at $233304.0 during Q4 2022, with a 5-year trough of -$343691.0 in Q2 2024.
  • In the last 4 years, Sunshine Biopharma's Tax Provisions had a median value of $31652.5 in 2023 and averaged $570.58.
  • Over the last 5 years, Sunshine Biopharma's Tax Provisions had its largest YoY gain of 42553.48% in 2024, and its largest YoY loss of 49199.68% in 2024.
  • Sunshine Biopharma's Tax Provisions (Quarter) stood at $233304.0 in 2022, then dropped by 5.59% to $220267.0 in 2023, then crashed by 158.45% to -$128737.0 in 2024, then dropped by 6.76% to -$137438.0 in 2025.
  • Its last three reported values are -$137438.0 in Q3 2025, -$209166.0 for Q2 2025, and -$40161.0 during Q1 2025.